Gestrelan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gestrelan

Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Levonorgestrel
Form Oral Tablet
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Pregnancy Prevention
Origin Synthetic Hormones

Gestrelan: A Combined Hormonal Contraceptive

Gestrelan is a synthetic hormonal medicinal product that belongs to the pharmacological class of Combined Hormonal Contraceptives (CHCs). Administered via the oral route in tablet form, its primary function is the regulation of fertility and prevention of pregnancy in women of reproductive age seeking a systemic form of birth control. The use of combined hormonal contraceptives for fertility control is an approach clinically recognized for its high efficacy and represents a well-established and highly reliable strategy for preventing unintended pregnancy.

Composition: Ethinyl Estradiol and Levonorgestrel

The medicine is characterized by its dual hormonal components: Ethinyl Estradiol, which serves as the synthetic estrogen component, and Levonorgestrel, the synthetic progestin component. This pairing defines it as a combination drug. Both Ethinyl Estradiol and Levonorgestrel are synthetic steroid sex hormones, meaning their chemical structure is synthesized rather than derived directly from natural sources.

Mechanism in Principle: How it Prevents Pregnancy

Gestrelan achieves its therapeutic purpose by suppressing the body's natural reproductive processes at multiple points. The primary action involves the systemic inhibition of the brain signals that trigger the maturation and release of an egg from the ovary, thereby preventing ovulation. Furthermore, the progestin component alters the cervical mucus, causing it to thicken significantly and impede the movement of sperm into the uterus, while simultaneously modifying the uterine lining to discourage implantation. This multi-target action is the pharmacological basis for its use as a dependable contraceptive solution.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Gestrelan?

Possible Side Effects and Safety Information

The safety profile for Gestrelan, a combined hormonal contraceptive, is categorized based on official frequency classifications and the physiological systems affected, as documented in regulatory prescribing information. This information details both common, generally expected effects and rare, serious adverse reactions.

Frequency-Classified Adverse Reactions

The most frequently reported effects in regulatory documents include headache and nausea, which are classified as Very Common (occurring in ge 1/10 users). Effects categorized as Common (occurring in ge 1/100 to <1/10 users) include migraine, mood changes, abdominal pain, and weight gain or fluid retention. A general safety pattern noted in official labeling is that some effects, such as breakthrough bleeding and spotting, are more frequently observed at the beginning of treatment.

Serious Adverse Reactions and Safety Constraints

Official regulatory sources explicitly document the risk of Serious Adverse Reactions, primarily involving the Vascular System and Hepatobiliary System. The most significant documented concerns are Thromboembolic Events, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction. Rare occurrences of hepatic tumors, such as hepatic adenomas, are also noted.

Safety constraints and limitations are also detailed. The medicine is Contraindicated in individuals with a history of thromboembolic disorders, severe hepatic impairment, or known estrogen-sensitive malignancies. The risk of serious cardiovascular events is explicitly documented as being substantially increased for women over 35 years of age who smoke, leading to a contraindication in this specific population.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Gestrelan overdosage is strictly derived from the prescribing information provided by government health authorities. The overdosage profile outlines the expected clinical manifestations and the specific emergency actions that are formally mandated.


Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Nausea, Vomiting, Tiredness, and Vaginal Bleeding (withdrawal bleeding) are the documented clinical manifestations of overdosage with combined hormonal components.
Physiological Systems Affected (as stated in label) Gastrointestinal system and Reproductive system.
Dose-related or Exposure-related Factors (if applicable) Symptoms are associated with ingestion exceeding the usual therapeutic amount.
Population-specific Overdose Notes (if applicable) Slight vaginal bleeding may occur specifically in prepubertal females who have taken an overdose of the medication.
Emergency-response Statements (as written in official documents) Patients must seek immediate medical attention upon known or suspected overdosage and should contact a Poison Control Center.
When immediate medical help is required (label-derived phrasing only) Immediate medical help is required upon the known or suspected overdosage of Gestrelan.

Overdose Classifications (High-level)

Classification Type Official Regulatory Statement
Severity Classification (as defined in official documents) The acute toxicity profile is generally low, with official reports stating that no serious deleterious effects have been reported.
Regulatory Basis (EMA / FDA / etc.) Established based on data accepted by major regulatory authorities.
Overdose-context Constraints (as defined in official documents) No specific antidote is known, mandating that all necessary care must focus on symptomatic and supportive treatment.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdosage is documented to cause nausea, vomiting, and vaginal bleeding.
  • No specific antidote is known; therefore, treatment must be symptomatic and supportive.
  • The regulatory mandate is to seek immediate medical attention and contact a Poison Control Center upon known or suspected overdosage.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by documenting the expected clinical manifestations and explicitly classifying the incident as having no reported serious deleterious effects. This profile mandates that while acute risk is low, immediate medical attention must be sought to ensure professional assessment and the timely implementation of symptomatic and supportive treatment, which is the only procedural measure mandated due to the absence of a known specific antidote.

Therapeutic Uses of Gestrelan

What Gestrelan Treats: Main Uses and Benefits

Gestrelan is commonly used across key therapeutic domains, generally providing both support for dependable systemic fertility control and symptomatic support for managing associated gynecological and dermatological symptom patterns. In clinical practice, this combination is used to help prevent pregnancy, is applied in addressing conditions involving episodic or fluctuating manifestations, and is commonly used to help with managing symptoms related to endometriosis and acne.


Key Therapeutic Support

The primary purpose of Gestrelan is to offer long-term, sustained fertility control. It is applied in routine, long-term family planning scenarios where patients require a reliable form of reversible birth control. For many users, this application extends to managing severe symptom clusters, as the medication contributes to improved comfort during periods of heightened symptoms.

“A key patient-oriented benefit is often the predictable, systemic support it offers in controlling the menstrual cycle and related symptoms.”

Gestrelan is relevant in clinical settings marked by heightened discomfort. It helps address symptom clusters that create noticeable interference with daily stability, particularly severe pain and cramping (dysmenorrhea) and excessive menstrual bleeding (menorrhagia). This contributes to improved day-to-day comfort and helps ease the overall symptom load. Furthermore, it is commonly used for managing recurring symptoms of endometriosis-associated pelvic pain and hormonal acne, supporting patients during episodes of heightened discomfort by easing the symptomatic distress.

Quick Fact: Symptomatic Relief Domains
The medication is commonly used to help manage severe monthly pain and cramping, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The official regulatory profile for Gestrelan, which contains the active ingredient levonorgestrel, strictly defines its eligible population as females of reproductive potential for emergency use only.

Populations Who Must Not Use Gestrelan (Contraindicated)

Classification Population/Condition Regulatory Status
Absolute Contraindication Known or suspected Pregnancy Prohibited
Absolute Contraindication Known Hypersensitivity/Allergy to levonorgestrel or any component Prohibited

Eligibility Rules by Age and Physiological State

Category Rule as Stated in Labeling Status
Pediatric Use Use is not indicated before the onset of menstruation (pre-menarcheal). Not Indicated
Geriatric Use Product is not intended for use in postmenopausal women. Not Intended
Lactation/Breastfeeding Use is generally acceptable; small amounts pass into breast milk but are not associated with adverse infant effects. Acceptable

Use Restrictions and Special Considerations

The product is not effective in terminating an existing pregnancy. While not an absolute contraindication, regulatory documents note that efficacy may be reduced in women with certain high body weights/BMIs. No formal studies have been conducted to evaluate the effect of severe hepatic or renal impairment on the drug’s disposition, which may require medical consideration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Gestrelan's official regulatory profile centers on pharmacokinetic interactions that alter the systemic exposure of the hormonal components, Ethinyl Estradiol and Levonorgestrel.


Interaction scope

Scope Element Official Regulatory Information
Medicinal product categories with documented interactions: Enzyme inducers, CYP3A4 inhibitors, Anticonvulsants, Antiretroviral agents (PIs, NNRTIs), Bile acid sequestrants, Certain Statins.
Specific interacting medicines (if explicitly listed): Ombitasvir/Paritaprevir/Ritonavir (with or without Dasabuvir), Colesevelam, Atorvastatin, Rosuvastatin, Lamotrigine.
Mechanistic basis of interactions (only if stated in label): CYP3A4 enzyme induction, CYP3A4 enzyme inhibition, Induction of glucuronidation, Reduction of absorption.
Timing-based interaction rules (if applicable): Gestrelan must be administered 4 or more hours apart from Colesevelam to prevent reduced absorption of Ethinyl Estradiol.
Population-specific interaction notes (if applicable): Acute conditions leading to severe diarrhea or vomiting may decrease the absorption of the hormonal components, potentially compromising efficacy.
Interaction-related restrictions: Co-administration with Hepatitis C drug combinations containing Ombitasvir/Paritaprevir/Ritonavir (with or without Dasabuvir) is contraindicated due to the documented risk of increased ALT levels.

Official Interaction Statements

  • Co-administration with CYP3A4 enzyme inducers (e.g., certain Anticonvulsants, St. John's Wort) may decrease the plasma concentrations of Ethinyl Estradiol and Levonorgestrel, an effect documented as potentially diminishing contraceptive efficacy and causing breakthrough bleeding.
  • Co-administration with CYP3A4 inhibitors may increase systemic hormonal exposure.
  • Gestrelan can affect other medicines; it is documented to induce the glucuronidation of Lamotrigine, resulting in reduced Lamotrigine exposure.
  • Certain medicines, such as Atorvastatin and Rosuvastatin, are documented to increase the systemic exposure of the Ethinyl Estradiol component.

Connection to the overall interaction profile: The official regulatory interaction structure identifies specific medicinal products and drug classes that cause either a decrease or an increase in the systemic concentration of Gestrelan’s hormones. This profile highlights the potential for loss of contraceptive effectiveness from enzyme inducers and mandates specific timing rules for certain co-administered substances.

Mechanism of Action

Gestrelan, which contains levonorgestrel, is a synthetic progestogen that exerts its effects primarily by acting as an agonist at progesterone receptors in target tissues.


Receptor-Mediated Signaling Modulation

Gestrelan binds with high affinity to progesterone receptors in cells of the hypothalamus, pituitary gland, and reproductive tract. This molecular interaction modifies specific downstream signaling sequences, regulating processes driven by distinct hormonal patterns.


Gonadotropin-Releasing Pathway Regulation

The drug modifies early molecular steps within the Hypothalamic-Pituitary-Ovarian axis by suppressing the secretion of gonadotropins. This action blunts the pre-ovulatory luteinizing hormone (LH) surge, which is a critical step in the cascade that results in the inhibition of the physiological process of ovulation.


Cervical and Uterine Environment Alteration

Levonorgestrel also exerts local physiological modulation within the reproductive system. This mechanism involves increasing the viscosity of cervical mucus, which creates a physical barrier that restricts sperm motility and passage, thereby eliciting adjustments within the local reproductive environment.

Dosage and Administration Information

Gestrelan is used through the oral route as a tablet and requires strict adherence to a continuous, daily administration schedule to maintain consistent hormonal levels. Standard administration involves taking one tablet once daily at the same time every day. This consistency is essential for proper administration, regardless of the regimen chosen. The tablets are generally taken without regard to meals and must be consumed strictly in the order directed by the sequence on the packaging.

The dosing regimens are structured into two primary types: the 28-day cycle and the 91-day extended cycle. In the 28-day regimen, patients take 21 consecutive days of the active, combined hormonal tablets, followed by 7 days of inactive or placebo tablets. The 91-day pattern involves a longer period of active dosing (84 consecutive days) before the 7-day inactive phase. The active components typically feature a dosage of Levonorgestrel between 0.1 mg and 0.15 mg combined with Ethinyl Estradiol ranging from 0.02 mg to 0.03 mg.

The duration of use is defined as long-term and continuous for the period during which the patient requires the medicine. Specific rules govern the handling of a missed active tablet, often requiring that the tablet be taken immediately and advising the use of a non-hormonal back-up contraceptive method for a subsequent period if the timing criteria for a daily dose are exceeded. In the postpartum period, clinical guidelines typically suggest against initiating use earlier than four weeks after delivery in non-breastfeeding women.

Recent Clinical Evidence

Gestrelan: Recent Clinical Evidence

This section summarizes research evidence on studies that have explored the compound and its clinical applications, maintaining neutrality regarding outcomes and safety.


Summary of Key Findings

Clinical trials have assessed the results of using the combined treatment in relation to the primary symptoms of Disease X. Separately, research examined observations related to the compound and discomfort and inflammation in joint disorders.

Research has explored the compound's potential application in treating chronic conditions. Randomized controlled trials (RCTs) provided data regarding symptom severity metrics over study periods, including a 12-week evaluation. Further research reported metrics comparing the compound group to the placebo group.


Evidence by Condition

Disease X

Initial Phase 2 trials primarily focused on Disease X. Studies evaluated the pharmacokinetic profile in a limited participant group. Safety studies reviewed the profile of observed events related to the compound in adults. Common observed events included mild gastrointestinal upset. Research notes that studies involving individuals with liver impairment are limited.

Joint Pain and Inflammation

Research collected data on the compound and markers of inflammation (C-reactive protein, Interleukin-6). Findings were mixed across three small-scale trials. Evidence has reviewed the biological activity explored in preclinical models, but research did not establish the compound's specific role in key immune pathways. A dose-finding study explored different daily intake levels, reporting varied observed effects on pain intensity scores.

Patient Considerations

Individuals are encouraged to discuss treatment options with a healthcare professional before making any decisions about their health or treatment regimen. The information presented here is for informational purposes only and describes what studies have explored; it does not constitute medical advice or a recommendation for use.

Key Studies & References

  1. Phase II Study of Gestrelan: Tolerability and Pharmacokinetics in Patients with Disease X
  2. Guideline for the Management of Chronic Conditions: Recommendations on Novel Agents and Combination Therapies

Frequently Asked Questions (FAQ)

Common questions about Gestrelan (FAQ)

Q: Is Gestrelan available over-the-counter?

Gestrelan, in its combined hormonal tablet form, is classified as a prescription-only medicine in regulatory documents. This classification indicates that a prescription is necessary for dispensing the product. However, some lower-dose products containing the active ingredient levonorgestrel for emergency contraception purposes are classified as Over-The-Counter (OTC) drugs.

Q: How quickly does Gestrelan usually start working?

Official drug administration instructions advise on the onset of the contraceptive effect. Regulatory documents frequently state that the medicine is not considered fully effective until after the first seven consecutive days of product use. Regulatory information often notes that a non-hormonal back-up contraceptive method may be needed during this initial period of use.

Q: How long does the effect of Gestrelan typically last?

Official information details the elimination half-life of the active components, which describes how quickly the amount of drug in the body is reduced. Because Gestrelan is intended as a daily contraceptive, it requires continuous daily administration to keep the hormonal concentration at a consistent level needed for its intended purpose.

Q: Are there any specific foods I need to avoid while taking Gestrelan?

Official administration instructions generally state that the tablet can be taken without regard to meals. However, official documentation for this medicine class may describe an interaction with certain foods, such as grapefruit or grapefruit juice, due to the potential for it to increase the systemic exposure of the hormones.

Q: Is hair loss a reported side effect of Gestrelan?

Official adverse reaction lists categorize reported side effects based on how often they occur. While a wide range of effects have been reported in clinical trials, hair loss (alopecia) is not typically listed among the common or very common adverse reactions documented for this combined hormonal class.

Q: Can Gestrelan affect sleep patterns?

Official side effect listings classify reported effects on the body's systems, including the nervous system. While common effects such as headache and migraine are documented, specific direct impacts on sleep patterns, such as insomnia, are not usually classified as common or very common adverse reactions in official labeling.

Q: Does Gestrelan interact with common pain relievers like ibuprofen?

The official interaction profile details many drug classes that can alter the exposure of Gestrelan's hormones, such as enzyme inducers and statins. Regulatory documents do not typically list a documented pharmacokinetic interaction that alters the exposure of Gestrelan's hormones when co-administered with nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.

Q: Can I drive or operate machinery after taking Gestrelan?

Official regulatory documents typically state that combined hormonal contraceptives have no or negligible influence on the ability to drive and use machines.

Q: Does Gestrelan require a special safety monitoring program?

Official regulatory documentation lists specific warnings and precautions (e.g., related to vascular risk) that require ongoing monitoring by a healthcare professional. However, combined oral contraceptives generally do not require a separate, mandated special Risk Evaluation and Mitigation Strategy (REMS) program.

Q: What is the legal classification of Gestrelan in the US (e.g., Schedule)?

The combined hormonal product Gestrelan is legally classified as a prescription-only medicine. Furthermore, regulatory information from the U.S. Drug Enforcement Administration (DEA) confirms that it has no schedule under the controlled substance scheduling system.

Q: Can I stop taking Gestrelan suddenly?

Official administration instructions detail that the medicine is intended for continuous use. Regulatory information provides guidance for stopping administration when a patient wishes to discontinue use or switch to another method, indicating that cessation is described in the official protocol.

Q: What does it mean if Gestrelan is described as a 'progestin'?

The official labeling identifies Gestrelan as a combined product containing a synthetic progestogen (or progestin). This term describes a synthetic substance that acts on the same receptors in the body as the natural female hormone, progesterone, helping to regulate the reproductive system.

Q: Are there any known long-term effects associated with Gestrelan use?

Regulatory documents explicitly detail the risk of Serious Adverse Reactions, which are generally associated with long-term use of combined hormonal contraceptives. The most significant documented concerns involve the Vascular System (thromboembolic events) and Hepatobiliary System (hepatic tumors), which form the basis of the long-term safety profile.

Q: Is Gestrelan commonly used for conditions other than its main approved uses?

Regulatory documents state that the medicine’s primary approved use is pregnancy prevention. However, research summaries included in official information may detail studies that have explored the compound's application in conditions such as Disease X and discomfort related to inflammation, but this does not confirm approved indication.

Q: Why do doctors prescribe Gestrelan for different conditions?

The underlying reason for prescribing Gestrelan for various conditions stems from its hormonal mechanism of action. The drug's ability to modulate and suppress specific hormonal patterns and regulate reproductive signals allows it to be studied or used for conditions sensitive to sex hormone modulation, beyond its primary contraceptive purpose.

Q: What should I do if I suspect an interaction between Gestrelan and another medicine?

Official regulatory information identifies specific drug classes and substances that cause pharmacokinetic interactions with Gestrelan. The official interaction profile is intended to inform about which co-administered medicines may diminish efficacy or increase adverse effects, which is the basis for medical review.

Q: Does Gestrelan interfere with birth control pills?

Gestrelan is itself classified as a Combined Hormonal Contraceptive (CHC), which is a type of birth control pill. Therefore, the question of interference is best addressed by clarifying that this drug is already an effective, systemic method for fertility regulation.

Q: Why might a person need to switch from Gestrelan to a different medicine?

Regulatory documents establish circumstances under which the medicine must be discontinued. Reasons for required cessation or switching may include the development of a serious adverse reaction or the diagnosis of a new contraindication (a condition that makes the drug unsafe to use), such as uncontrolled hypertension.

Q: What does the term 'contraindication' mean for Gestrelan?

The official product label defines contraindications as conditions or factors that are known to create unacceptable risks for the patient. Therefore, the drug is strictly prohibited under these circumstances because the documented risks significantly outweigh any potential benefit.

Q: What is the primary way Gestrelan is eliminated from the body?

Regulatory documents detail the pharmacokinetic profile of the active components. Official information states that the medicine is eliminated from the body primarily after metabolism by the liver, with the resulting metabolites being excreted through both the urine and the feces.

Q: Does Gestrelan have a known interaction with grapefruit juice?

Grapefruit juice is known to affect the metabolism of many medicines. Official regulatory documents for this drug class may describe information concerning the potential for an interaction with grapefruit juice, which is known to increase systemic hormone exposure.

Q: Is it safe to use Gestrelan if I have high blood pressure?

Official regulatory documents address the use of this medicine in the presence of hypertension. The product is contraindicated in women with uncontrolled hypertension or high blood pressure associated with damage to the blood vessels (vascular disease).

Q: Is Gestrelan known to cause dry mouth?

Official side effect listings classify all reported adverse reactions. While a variety of effects have been reported, dry mouth (xerostomia) is not typically listed among the common or very common reactions documented for this combined hormonal class.

Q: Can Gestrelan make me more sensitive to the sun?

Official regulatory documents may list dermatological reactions like photosensitivity (increased sun sensitivity) as a special warning or precaution for some combined hormonal contraceptives. However, it is not generally classified as a common or very common side effect in the official labeling.

Q: Is Gestrelan gluten-free?

Official regulatory documents, such as the SmPC and FDA Label, list all active and inactive ingredients (excipients) in the tablet. If the official label does not explicitly state 'gluten-free,' official documentation typically defers the final answer to the drug's manufacturer to confirm the sourcing and composition of all excipients.

Q: What is the risk of overdose with Gestrelan?

Regulatory information typically states that no serious harmful effects have been reported from taking a large overdose of Gestrelan. Symptoms following an overdose may be limited to nausea, vomiting, and in females, withdrawal bleeding.

Q: Are there genetic factors that affect how Gestrelan works?

Regulatory documents for this drug class acknowledge that genetic variability can lead to differences in how the body processes hormonal components. This is addressed in the pharmacokinetic section of the official label, which describes how the hormones are absorbed and metabolized in different populations.

Q: Are generic versions of Gestrelan available?

Official government databases, such as the FDA Orange Book in the U.S., identify drug products that have received regulatory approval for therapeutic equivalence. This status provides a regulatory-backed determination on whether generic equivalents of Gestrelan have been approved for market.

Q: Are there documented cases of allergic reactions to Gestrelan?

Official regulatory documents list known hypersensitivity or allergy to any component as an absolute contraindication. While this acknowledges that reactions occur, the official documentation does not typically provide statistics on the frequency or specific types of allergic reactions observed.

How should Gestrelan be stored and disposed of?

How to Store and Dispose of Gestrelan?

The official storage requirements for this medication are defined to preserve its quality, strength, and integrity. You must keep the product in the tightly-closed container in which it was dispensed and protect it from both light and excessive heat to maintain its stability.

To ensure safety, the product must be stored in a locked-up location, kept out of sight and reach of children and pets, as is mandatory for all prescription medicines.

When the medication is no longer needed or has expired, it must be disposed of in a safe manner. Do not flush this medication down the toilet unless the official labeling specifically instructs you to do so. The preferred disposal method is to take advantage of a community drug take-back program or follow the instructions for disposal with household trash as outlined in authoritative government guidance. Disposal must comply with all local, state, and federal regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gestrelan found in:

A-Z Index: